国产地西他滨治疗老年急性髓系白血病的疗效及安全性  

Efficacy and safety analysis of decitabine in treating elderly acute myeloid leukemia patients

作　　者：单学赟[1] 周茉[1] 孙乃同[1] 王纯斌[1] 邵钰[1] 周燕[1] 杨小燕[1] 盛薇薇[1] 

机构地区：[1]盐城市第三人民医院血液科,江苏盐城224000

出　　处：《现代肿瘤医学》2016年第24期3985-3988,共4页Journal of Modern Oncology

摘　　要：目的:探讨以国产地西他滨为基础的化疗方案治疗老年急性髓系白血病(AML)的临床疗效及安全性。方法:回顾性分析2013年1月-2016年2月收治的老年急性髓系白血病患者29例,根据其是否使用国产地西他滨分组,对比评定疗效。结果:地西他滨组和传统方案组的完全缓解率分别为60.0%(6/10)和35.7%(5/14),差异有统计学意义(P<0.05);同时比较两组的总生存期(OS),差异有统计学意义(P<0.05)。80%的老年AML患者在使用以国产地西他滨为基础的化疗方案治疗过程出现不同程度的不良反应,多为Ⅰ-Ⅱ级,少数患者发生了Ⅲ-Ⅳ级不良反应,主要为中性粒细胞减少和血小板减少。结论:以国产地西他滨为基础的化疗方案有较高的缓解率,且延长生存期。Objective： To evaluate the efficacy and safety of decitabine in elderly acute myeloid leukemia patients. Methods： To retrospectively analyze 29 elde rly acute myeloid leukemia patients in our hospital from 2013 to 2016, then and the cl inical outments and adverse reactions. Results ： The CR of decitabine group and Conventional group were 60. 0% （6/10） ,35.1% （5/14） ,re spectively,with statistical significance （P 〈0. 05） . The results of OR between two groups also with statistical significance （ P 〈0. 05） . Adverse events （A E ） were identified in 80. 0 % patients during decitabine retreatment,including diarrhea and thrombocytopenia,30. 0 % （3 patients） were 3/4 grade of A E . Conclusion ： Decitabine regimen is with a higher response rate in elde rly transformed patients with no more adverse events.

关 键 词：地西他滨 急性髓系白血病 老年患者 

分 类 号：R[医药卫生]